Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
AstraZeneca gets new Tagrisso OK as drug succeeds in improving outcomes for EGFR-mutated non-small cell lung cancer
AstraZeneca's Tagrisso, approved by the FDA for use with chemotherapy, shows improved outcomes for EGFR-mutated non-small cell lung cancer, extending progression-free survival by nine months over monotherapy. New trial data supports its early use and effectiveness in unresectable cases, reinforcing its status as a key treatment.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript
Halozyme Therapeutics reported strong Q4 and full-year 2023 results, with a 26% revenue increase to $829M and a 24% rise in royalty revenue to $448M. The company highlighted growth from its ENHANZE technology and commercial products, projecting 2024 revenue between $915M and $985M. Key achievements include advancements in subcutaneous drug delivery and partnerships, with a focus on expanding its pipeline and leveraging its high-volume auto-injector technology.
Amgen: Relative Valuation Remains Unattractive
Amgen Inc., a biopharmaceutical company, saw its share price rise due to the $27.8 billion acquisition of Horizon Therapeutics and strong demand for its drugs. Despite raising its 2023 revenue guidance, Amgen faces risks from declining sales of immunology products, high debt, and upcoming competition from Prolia biosimilars. The company's valuation remains unattractive, with a 'market perform' rating advised.
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's Tagrisso
Johnson & Johnson's Rybrevant showed similar effectiveness to AstraZeneca's Tagrisso in treating advanced EGFR mutant NSCLC, with both drugs shrinking or halting tumor growth in about 75% of patients after a year. Rybrevant, approved in 2021 as a second-line treatment, may now also serve as an initial treatment option alongside Tagrisso, offering more effective choices to extend patient lives.
Top 10 Projected Best-Selling Drugs in 2024
Nature Reviews Drug Discovery forecasts the top 10 pharmaceutical products for 2024, each expected to surpass $10 billion in sales. Leading the list is Keytruda by Merck & Co., with a projected $27.19 billion in sales, followed by Ozempic, Dupixent, Eliquis, Biktarvy, Darzalex, Opdivo, Comirnaty, Gardasil, and Skyrizi. These drugs cover a range of treatments from cancer to diabetes, HIV, and COVID-19, highlighting significant advancements and market potentials in the pharmaceutical industry.
BrainChild Bio spins out of Seattle Children's to develop CAR-T cell therapies for pediatric brain tumors
Seattle Children's Hospital launches BrainChild Bio, a biotech startup focusing on CAR-T cell therapies for pediatric brain tumors, leveraging technology and funding from the hospital. With prior clinical testing and plans for future trials, BrainChild aims for accelerated approval, despite FDA scrutiny over CAR-T therapy's safety risks.
Ground-Breaking Release of World's Largest Whole Genome Sequences
The UK Biobank released nearly half a million whole genome sequences, the largest dataset of its kind, offering insights into disease causes and therapeutic targets. Funded by the UK government, Wellcome, and biopharmaceutical companies, this £200m project enables global researchers to access data for health research, promising transformative results for diagnoses and treatments.
Sickle Cell Disease Treatment Market Size to Garner Significant Growth by 2032
The global sickle cell disease (SCD) treatment market, valued at USD 2.5 billion in 2022, is projected to reach USD 50.45 billion by 2032, growing at a CAGR of 35.1%. North America led with a 36% market share in 2022. Growth factors include market expansion in developing regions, innovative therapies, and global health initiatives. Key treatments involve blood transfusion and bone marrow transplant, with hospitals and specialty clinics as primary end-users. Advances in genetic research and personalized medicine are driving market evolution, despite challenges like economic barriers and inadequate infrastructure in developing regions.
In lung cancer, J&J data amount to latest salvo against AstraZeneca
Johnson & Johnson and AstraZeneca compete in targeted lung cancer treatments. J&J presented successful studies of Rybrevant for non-small cell lung cancer with EGFR mutations at ESMO, suggesting its potential as a standard treatment.
© Copyright 2025. All Rights Reserved by MedPath